Mendus AB (publ) (IMMU) - Total Liabilities

Latest as of March 2026: Skr69.03 Million SEK ≈ $7.43 Million USD

Based on the latest financial reports, Mendus AB (publ) (IMMU) has total liabilities worth Skr69.03 Million SEK (≈ $7.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Mendus AB (publ) growing its equity to track the company's year-over-year net asset growth rate.

Mendus AB (publ) - Total Liabilities Trend (2009–2025)

This chart illustrates how Mendus AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See Mendus AB (publ) free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Mendus AB (publ) Competitors by Total Liabilities

The table below lists competitors of Mendus AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Marketwise Inc
NASDAQ:MKTW
USA $428.81 Million
Telcoware
KO:078000
Korea ₩24.75 Billion
Atakule Gayrimenkul Yatirim Ortakligi AS
IS:AGYO
Turkey TL17.91 Million
Cokal Ltd
AU:CKA
Australia AU$64.22 Million
Mad Paws Holdings Ltd
AU:MPA
Australia AU$16.09 Million
HPQ SILICON INC.
F:O08
Germany €3.34 Million
Native Mineral Resources Holdings Ltd
AU:NMR
Australia AU$27.92 Million

Liability Composition Analysis (2009–2025)

This chart breaks down Mendus AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Mendus AB (publ) (IMMU) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.53 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.12 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mendus AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mendus AB (publ) (2009–2025)

The table below shows the annual total liabilities of Mendus AB (publ) from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 Skr43.26 Million
≈ $4.66 Million
-15.54%
2024-12-31 Skr51.22 Million
≈ $5.51 Million
-0.02%
2023-12-31 Skr51.23 Million
≈ $5.51 Million
-51.65%
2022-12-31 Skr105.95 Million
≈ $11.40 Million
+64.92%
2021-12-31 Skr64.24 Million
≈ $6.91 Million
-4.92%
2020-12-31 Skr67.57 Million
≈ $7.27 Million
+117.62%
2019-12-31 Skr31.05 Million
≈ $3.34 Million
-29.96%
2018-12-31 Skr44.33 Million
≈ $4.77 Million
-21.66%
2017-12-31 Skr56.59 Million
≈ $6.09 Million
+194.98%
2016-12-31 Skr19.18 Million
≈ $2.06 Million
+27.39%
2015-12-31 Skr15.06 Million
≈ $1.62 Million
+135.04%
2014-12-31 Skr6.41 Million
≈ $689.52K
-31.06%
2013-12-31 Skr9.29 Million
≈ $1.00 Million
+344.35%
2012-12-31 Skr2.09 Million
≈ $225.08K
+26.97%
2011-12-31 Skr1.65 Million
≈ $177.28K
-29.20%
2010-12-31 Skr2.33 Million
≈ $250.40K
+113.00%
2009-12-31 Skr1.09 Million
≈ $117.56K
--

About Mendus AB (publ)

ST:IMMU Sweden Biotechnology
Market Cap
$43.53 Million
Skr404.47 Million SEK
Market Cap Rank
#22372 Global
#425 in Sweden
Share Price
Skr6.60
Change (1 day)
-4.90%
52-Week Range
Skr3.96 - Skr10.02
All Time High
Skr737.49
About

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more